The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Imfinzi (durvalumab) Market From 2026 To 2030?
The imfinzi (durvalumab) market size has expanded considerably in recent years. It is projected to grow from $3.01 million in 2025 to $3.36 million in 2026, exhibiting a compound annual growth rate (CAGR) of 11.4%. This historical growth can be linked to the clinical achievements of immune checkpoint inhibitors, the increasing prevalence of lung cancer, various regulatory approvals within oncology, improved patient survival outcomes, and robust pharmaceutical investment.
The Imfinzi (durvalumab) market size is projected to undergo rapid expansion in the upcoming years, with an anticipated increase to **$5.11 million in 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%.** This growth within the forecast period is attributable to several factors, including its expansion into new cancer indications, enhanced accessibility to immunotherapy, an increase in oncology clinical trials, rising healthcare spending in oncology, and the development of combination treatment protocols. Significant trends expected during this period involve the growing adoption of PD-L1 inhibitors, the broader application of immunotherapy in lung cancer, the emergence of combination immuno-oncology regimens, a heightened focus on biomarker-driven therapies, and its expanded use across multiple solid tumors.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp
What Influential Factors Are Boosting The Imfinzi (durvalumab) Market Demand?
The rising occurrence of cancer is projected to fuel the expansion of the Imfinzi (durvalumab) market in the future. Cancer encompasses a range of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body, capable of infiltrating and damaging healthy tissues. The increasing prevalence of cancer is primarily attributable to an aging demographic, given that cancer risk escalates with age, alongside lifestyle elements such as tobacco use, poor nutrition, and excessive weight, all of which contribute to elevated cancer rates. Imfinzi (durvalumab) addresses cancer by impeding the PD-L1 protein, thereby hindering cancer cells from bypassing detection by the immune system. As an illustration, in May 2024, the National Cancer Institute (NIH), a U.S. government entity, reported that the U.S. had 18.1 million cancer survivors in 2022, a number anticipated to climb to 22.5 million by 2032. Consequently, the increasing incidence of cancer is propelling the growth of the Imfinzi (durvalumab) market.
How Does Segment Analysis Break Down The Imfinzi (durvalumab) Market Structure?
The imfinzi (durvalumab) market covered in this report is segmented –
1) By Type: 2.4mL Injection, 10mL Injection
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications
What Trends Are Influencing The Imfinzi (durvalumab) Market?
Major companies operating in the Global Imfinzi (durvalumab) market are emphasizing indication expansion, such as its use in perioperative settings in combination with chemotherapy, to achieve a competitive advantage. For instance, in January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, announced that IMFINZI along with chemotherapy more than doubled the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers when compared to chemotherapy alone, involving a two-phase treatment (pre-surgery and post-surgery) and delivering a sustained immune activation benefit. This move into gastrointestinal cancer treatment areas highlights AstraZeneca’s strategy to broaden its clinical presence and drive long-term product adoption. However, this approach also introduces regulatory risks, as the more complex treatment regimens demand additional trial data and health economic validation.
Who Are The Firms Contributing To The Imfinzi (durvalumab) Market Ecosystem?
Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.
Access The Complete Imfinzi (durvalumab) Market Report:
https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report
Which Geographic Region Represents The Largest Imfinzi (durvalumab) Market Share?
North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model